Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 0/5 criteria met. Data as of 01/11/2026.
- ❌ Price trend failed
- ⚠️ Mixed growth
- ❌ Debt failed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: -55.15%
Price change 2019 → 2020: -37.56%
Price change 2020 → 2021: 35.77%
Price change 2021 → 2022: -84.41%
Price change 2022 → 2023: -61.55%
Price change 2023 → 2024: -91.51%
Price change 2024 → 2025: 52.94%
Price change 2025 → 2026: 170.77%
Price change 2026 (year to date): 170.77%
Financial growth
Revenue CAGR (8 years): 37.86%
Earnings CAGR (8 years): N/A
Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.
Debt
Negative or zero equity.
P/E (Price/Earnings)
P/E ratio: -0.39
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 57.59% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="EMMA" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Emmaus Life Sciences, Inc. | – | – | +21.9 % | 🔒 |
| Spineway S.A. | – | 0.07 | +9.3 % | – |
| SpineGuard S.A. | – | 0.27 | +1.6 % | – |
| Aelis Farma S.A. | – | 1.49 | +49.1 % | – |
| Biosynex S.A. | – | 1.90 | +35.4 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Emmaus Life Sciences, Inc. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 23.2 m | 1.4 m | 5.8 % | n/a |
| 2021 | 20.6 m | -15.9 m | -77.4 % | -11.0 % |
| 2022 | 18.4 m | -10.6 m | -57.8 % | -10.8 % |
| 2023 | 29.6 m | -3.7 m | -12.6 % | +60.9 % |
| 2024 | 16.7 m | -6.5 m | -38.8 % | -43.7 % |
| 2025 | 12.5 m | -7.5 m | -60.2 % | -25.2 % |
Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Emmaus Life Sciences, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 2.3 m | 2.0 m | 2.5 m | 1.4 m | 2.1 m |
| Total Debt | 29.9 m | 30.8 m | 32.6 m | 33.0 m | 32.6 m |
| Net Debt | 27.6 m | 28.8 m | 30.1 m | 31.6 m | 30.4 m |
| Equity | -21.4 m | -34.1 m | -47.8 m | -56.5 m | -63.6 m |
| Total assets | 56.7 m | 48.2 m | 35.2 m | 23.6 m | 21.4 m |
| Operating cash flow | -1.3 m | -5.1 m | -1.5 m | -2.3 m | -11,000 |
| Investments (capex) | 73,000 | 26,000 | 17,000 | 12,000 | 1,000 |
| Free cash-flow | -1.3 m | -5.1 m | -1.5 m | -2.3 m | -12,000 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.
Valuation and competitors
Emmaus Life Sciences, Inc. compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| Emmaus Life Sciences, Inc. | 1.6 m | n/a | -60.2 % |
| SQZ Biotechnologies Company SQZB | 707,787 | n/a | n/a |
| Orgenesis Inc. ORGS | 3.7 m | n/a | n/a |
| Bio-Path Holdings, Inc. BPTH | 15,089 | n/a | 0.0 % |
| Yulong Eco-Materials Limited YECO | 4,090 | n/a | n/a |
| Viropro Inc. VPRO | 25,404 | n/a | n/a |
| Helix BioMedix, Inc. HXBM | 739,289 | n/a | -68.3 % |
| Vibe Growth Corporation VIBEF | 391,931 | n/a | -14.0 % |
| Nutra Pharma Corp. NPHC | 1.4 m | n/a | -531.4 % |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.
Dividends and earnings
Emmaus Life Sciences, Inc.: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Earnings releases
| Date | Published EPS | Expected EPS | Surprise |
|---|---|---|---|
| 14/08/2026 | 0.02 | -0.06 | n/a |
| 15/05/2026 | -0.05 | -0.06 | n/a |
| 30/03/2026 | -0.03 | 0.01 | -400.0 % |
| 14/08/2025 | -0.02 | 0.01 | -300.0 % |
| 14/04/2025 | 0.04 | 0.03 | +33.3 % |
| 19/11/2024 | -0.01 | 0.01 | -200.0 % |
Stock splits
| Date | Operation |
|---|---|
| 18/07/2019 | reverse split: 1 share for 6 |
| 21/09/2016 | reverse split: 1 share for 200 |
| 03/04/2012 | reverse split: 1 share for 30 |
| 10/01/2007 | reverse split: 1 share for 50 |
| 15/06/2004 | reverse split: 1 share for 35 |
Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Emmaus Life Sciences, Inc.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 14/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Emmaus Life Sciences, Inc.
What is the Emmaus Life Sciences, Inc. share price?
Latest recorded price: 0.0230 USD on 13/11/2026, for a market cap of 1.6 m USD.
What is the revenue of Emmaus Life Sciences, Inc.?
12.5 m USD for fiscal year 2025, with net income of -7.5 m USD (net margin -60.2 %).
Is Emmaus Life Sciences, Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US29137T1016).
How many employees does Emmaus Life Sciences, Inc. have?
34 full-time employees according to the latest published profile.
Who runs Emmaus Life Sciences, Inc.?
Willis C. Lee is the company's chief executive.